Research Paper Volume 15, Issue 23 pp 14242—14262
Two lncRNA signatures with cuproptosis as a novel prognostic model and clinicopathological value for endometrioid endometrial adenocarcinoma
Figure 6. Chemotherapy drug response prediction for EEA in high- and low-risk EEA patients. (A) BMS345541. (B) NPK76-II-72-1. (C) AP-24534. (D) AKT inhibitor VIII. (E) BX-912. (F) XL-184. (G–L) Correlation analysis between risk group and 6 chemotherapy drugs.